You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
AstraZeneca
Merck
Colorcon
Boehringer Ingelheim

Last Updated: October 28, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,010,537

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,010,537 protect, and when does it expire?

Patent 10,010,537 protects CLEVIPREX and is included in one NDA.

This patent has twenty-six patent family members in seventeen countries.

Summary for Patent: 10,010,537
Title:Clevidipine emulsion formulations containing antimicrobial agents
Abstract: Pharmaceutical formulations comprising clevidipine and an antimicrobial agent exhibit a reduced propensity for microbial growth and provide increased convenience to health care workers administering clevidipine-containing formulations to patients.
Inventor(s): Motheram; Rajeshwar (Randolph, NJ), Williams; Gregory Charles (Bernardsville, NJ)
Assignee: Chiesi Farmaceutici S.p.A. (Parma, IT)
Application Number:13/270,004
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,010,537
Patent Claim Types:
see list of patent claims
Formulation;

Drugs Protected by US Patent 10,010,537

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Chiesi CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-001 Aug 1, 2008 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Chiesi CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-002 Aug 1, 2008 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Chiesi CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-003 Nov 8, 2013 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,010,537

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2011313852   Start Trial
Brazil 112013008601   Start Trial
Canada 2814495   Start Trial
China 103237446   Start Trial
Denmark 2627173   Start Trial
Eurasian Patent Organization 022849   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Medtronic
McKesson
Colorcon
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.